FBIO - コロナド・バイオサイエンシズ （Fortress Biotech Inc.） コロナド・バイオサイエンシズFBIOのチャート
FBIOの企業情報
| symbol | FBIO |
|---|---|
| 会社名 | Fortress Biotech Inc （コロナド・バイオサイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 フォートレス・バイオテック(Fortress Biotech Inc.) は新規医薬品とバイオテクノロジー製品を取得、開発、および商業化するバイオ医薬品会社である。特定の子会社を通じて製品を開発し、商品化する。Fortressには、免疫腫瘍学、血液学、遺伝子治療、疼痛管理、希少疾患及び皮膚科の6つの治療領域を対象とした、4つの商業ステージプログラム、25の開発ステージプログラムを含む11の事業子会社がある。Fortressは、内部開発プログラムに加えて、バイオ医薬ビジネスの専門知識と医薬品開発能力を活用し、Fortress Companiesを支援するための資金調達と管理サービスを提供する。同社の子会社には、Aevitas Therapeutics Avenue Therapeutics Caelum Biosciences Cellvation Inc. Checkpoint Therapeutics Cyprium Therapeutics Helocyte Inc. Journey Medical Corporation Mustang Bio National Holdings Corp 及び Tamid Bio Inc.を含む。 コロナド・バイオサイエンシズは、米国の生物学的薬剤メ―カ―。自己免疫疾患および癌の治療のための免疫療法と薬剤の開発に焦点を当てる。臨床開発段階の主要な製品候補は、クロ―ン病、潰瘍性大腸炎、多発性硬化症などの自己免疫疾患の治療向けCNDO-201、急性骨髄性白血病の治療向けCNDO-109。 Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company that was ranked in Deloitte's 2019 and 2020 Technology Fast 500™, annual rankings of the fastest- growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high- potential marketed and development-stage drugs and drug candidates. The company has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children's Research Hospital and Nationwide Children's Hospital. |
| 本社所在地 | 2 Gansevoort Street 9th Floor New York NY 10014 USA |
| 代表者氏名 | Lindsay A. Rosenwald Lindsay A. Rosenwald |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 781-652-4500 |
| 設立年月日 | 38869 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 45人 |
| url | www.fortressbiotech.com |
| nasdaq_url | https://www.nasdaq.com/symbol/fbio |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -117.12600 |
| 終値（lastsale） | 1.37 |
| 時価総額（marketcap） | 74449346.93 |
| 時価総額 | 時価総額（百万ドル） 52.44603 |
| 売上高 | 売上高（百万ドル） 211.46400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -0.92697 |
| 当期純利益 | 当期純利益（百万ドル） -37.95800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Fortress Biotech Inc revenues increased 25% to $119.3M. Net loss increased 45% to $42.6M. Revenues reflect National segment increase of 21% to $106.5M Dermatology Product segment increase of 99% to $12.2M. Higher net loss reflects Research and developement increase from $15.6M to $39.3M (expense) Total National operating expenses increase of 17% to $107.1M (expense). |
FBIOのテクニカル分析
FBIOのニュース
Fortress Biotech Non-GAAP EPS of -$0.33 misses by $0.18, revenue of $75.7M misses by $23.67M 2023/03/31 04:31:03 Seeking Alpha
Fortress Biotech press release (FBIO): FY Non-GAAP EPS of -$0.33 misses by $0.18.Revenue of $75.7M (+10.0% Y/Y) misses by $23.67M.As of December 31, 2022, Fortress’ consolidated…
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights 2023/03/30 20:10:00 GlobeNewswire
Fortress expects to file a total of three new drug applications in 2023
Is Fortress Biotech Inc. (NASDAQ:FBIO) stock a better investment at this time? 2023/02/27 17:32:00 US Post News
Currently, Fortress Biotech Inc.’s (FBIO) stock is trading at $0.78, marking a gain of 18.70% from last night’s close. At this price, the stock is -55.68% below its 52-week high of $1.76 and 62.43% above its 52-week low of $0.48. Based on the past 30-day period, the stock price is -19.72% below the high and […]
Charming stocks: Cerberus Cyber Sentinel Corporation (NASDAQ:CISO -9.50%), Fortress Biotech, Inc. (NASDAQ:FBIO -1.16%) 2023/02/23 15:30:41 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Charming stocks: Cerberus Cyber Sentinel Corporation (NASDAQ:CISO -9.50%), Fortress Biotech, Inc. (NASDAQ:FBIO -1.16%) appeared first on Stocks Equity .
Hypnotizing stocks: HEXO Corp. (NASDAQ:HEXO), Fortress Biotech, Inc. (NASDAQ:FBIO) 2023/02/20 12:59:00 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Hypnotizing stocks: HEXO Corp. (NASDAQ:HEXO), Fortress Biotech, Inc. (NASDAQ:FBIO) appeared first on Stocks Equity .
Investing in Fortress Biotech Inc. (FBIO) might be a great opportunity, but the stock is a bit undervalued 2022/12/29 14:32:00 US Post News
In Wednesday’s session, Fortress Biotech Inc. (NASDAQ:FBIO) marked $0.48 per share, down from $0.52 in the previous session. While Fortress Biotech Inc. has underperformed by -6.43%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, FBIO fell by -80.07%, with highs and lows ranging from $2.78 to […]
Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors 2022/12/19 13:00:00 GlobeNewswire
MIAMI, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lucy Lu, M.D., has been appointed to its Board of Directors. Dr. Lu is an accomplished executive with over 20 years of experience in a wide range of financial and drug development matters in the biotech and healthcare sectors as an investment banker, equity research analyst and executive at several biotech companies.
Fortress Biotech Inc. (NASDAQ:FBIO) Shares Plunged -15.60% In A Week – But Will They Keep Going Up? 2022/12/17 13:00:00 Marketing Sentinel
In last trading session, Fortress Biotech Inc. (NASDAQ:FBIO) saw 0.31 million shares changing hands with its beta currently measuring 1.79. Company’s recent per share price level of $0.58 trading at -$0.02 or -3.48% at ring of the bell on the day assigns it a market valuation of $66.02M. That closing price of FBIO’s stock is … Fortress Biotech Inc. (NASDAQ:FBIO) Shares Plunged -15.60% In A Week – But Will They Keep Going Up? Read More »
Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference 2022/12/06 13:30:00 GlobeNewswire
MIAMI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Fortress will participate in one-on-one meetings at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference, which is being held on Thursday, December 8, 2022 in Miami, FL.
Was anything negative for Fortress Biotech Inc. (FBIO) stock last session? 2022/11/30 12:40:00 US Post News
The share price of Fortress Biotech Inc. (NASDAQ:FBIO) fell to $0.65 per share on Tuesday from $0.70. While Fortress Biotech Inc. has underperformed by -6.69%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, FBIO fell by -76.70%, with highs and lows ranging from $2.96 to $0.67, […]
Was anything negative for Fortress Biotech Inc. (FBIO) stock last session? 2022/11/30 12:40:00 US Post News
The share price of Fortress Biotech Inc. (NASDAQ:FBIO) fell to $0.65 per share on Tuesday from $0.70. While Fortress Biotech Inc. has underperformed by -6.69%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, FBIO fell by -76.70%, with highs and lows ranging from $2.96 to $0.67, […]
Fortress Biotech Non-GAAP EPS of -$0.08 misses by $0.01, revenue of $16.5M misses by $5.13M 2022/11/15 09:13:38 Seeking Alpha
Fortress Biotech press release (FBIO): Q3 Non-GAAP EPS of -$0.08 misses by $0.01.Revenue of $16.5M (-21.8% Y/Y) misses by $5.13M.As of September 30, 2022, Fortress’ consolidated…
Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights 2022/11/14 21:01:00 GlobeNewswire
Net revenue for the nine months of 2022 increased 17.5% period-over-period to $59.3 million
Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript 2022/11/11 03:42:05 Seeking Alpha
Fortress Biotech, Inc. (NASDAQ:NASDAQ:FBIO) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Co-Founder President…
EQS-News: Fortress Biotech, Inc.: Fortress Bio''s Portfolio Of Marketed Drugs Could Soon See Three Additions 2022/10/06 12:04:00 Finanz Nachrichten
EQS-News: Fortress Biotech, Inc. Fortress Bio''s Portfolio Of Marketed Drugs Could Soon See Three Additions 06.10.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this anno…